Selective cyclooxygenase inhibitors: current status.

Area of Science:

• Pharmacology
• Gastroenterology

Background:

• Aspirin and NSAIDs are effective analgesics and anti-inflammatories but cause gastric ulcers via COX inhibition.
• Developing safer NSAIDs targeting COX enzymes has been a long-standing goal in drug design.

Purpose of the Study:

• To review the development and therapeutic role of selective cyclooxygenase-2 (COX-2) inhibitors.
• To discuss the physiological functions, side effects, and withdrawal reasons of COX-2 inhibitors.

Main Methods:

• Literature review of COX-2 inhibitors.
• Analysis of drug mechanisms, efficacy, and safety profiles.

Main Results:

• Selective COX-2 inhibitors (Coxibs) were developed in the late 1990s.
• Coxibs demonstrated efficacy comparable to NSAIDs with reduced gastrointestinal side effects.

Conclusions:

• COX-2 inhibitors represent a significant advancement in developing safer anti-inflammatory and analgesic drugs.
• Understanding their physiological roles and side effects is crucial for safe clinical use and future drug development.